A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
Prof. Dr. med. Florian Roghmann
E-Mail: florian.roghmann@
elisabethgruppe.de
Katja Fritz
Gesamtleitung Studienkoordination
Fon: 0 23 02 - 173 -13 27
E-Mail: studienkoordination@
elisabethgruppe.de